Abstract: The process of the present invention is used to prepare agglomerated, crystalline particles of medium chain fatty acid sodium salts, such as sodium caprate. This process comprises the steps of: a) dissolving a medium chain fatty acid in a first solvent to produce a first solution, wherein the first solvent comprises an aprotic polar solvent; b) adding to the first solution (i) a second solvent, wherein the second solvent comprises a medium chain aliphatic hydrocarbon solvent, and (ii) a solution comprising a sodium salt of a short chain alcohol to create a resulting slurry; and c) isolating agglomerated crystals from the resulting slurry. The first solvent may comprise acetonitrile, and the second solvent may comprise heptane. Further provided are products generated by this process, including sodium caprate products having superior flowability and compression properties.

Abstract: The present invention relates to efficient synthetic processes useful in the preparation of Compound A, a BTK inhibitor of Formula (I): or a pharmaceutically acceptable salt thereof, including the preparation of intermediates used to make Compound A or a pharmaceutically acceptable salt thereof.

Abstract: The present invention provides a novel crystalline form of verubecestat (Crystalline Form II of Verubecestat) and pharmaceutically acceptable compositions thereof, each of which may be useful in treating, preventing, ameliorating, and/or delaying the onset of an A? pathology and/or a symptom or symptoms thereof. Non-limiting examples of such A? pathologies, including Alzheimer's disease and mild cognitive impairment, are disclosed herein.

Abstract: The present invention provides a novel crystalline form of verubecestat (Crystalline Form II of Verubecestat) and pharmaceutically acceptable compositions thereof, each of which may be useful in treating, preventing, ameliorating, and/or delaying the onset of an A? pathology and/or a symptom or symptoms thereof. Non-limiting examples of such A? pathologies, including Alzheimer's disease and mild cognitive impairment, are disclosed herein.

Abstract: The instant invention relates to crystalline forms of MK-1775, an inhibitor of Weel kinase. Specifically, the instant invention relates to hemihydrates of MK-1775.

Abstract: The instant invention relates to crystalline forms of MK-1775, an inhibitor of Weel kinase. Specifically, the instant invention relates to hemihydrates of MK-1775.

Abstract: The instant invention relates to crystalline forms of MK-1775, an inhibitor of Weel kinase. Specifically, the instant invention relates to hemihydrates of MK-1775.

Abstract: The instant invention relates to crystalline forms of MK-1775, an inhibitor of Weel kinase. Specifically, the instant invention relates to hemihydrates of MK-1775.

Abstract: Heavy fractions of paraffinic lubes produced over dewaxing catalysts are effective as wax crystal modifiers for being hydrocarbons notwithstanding that such heavy fractions have pour points above that of the liquid hydrocarbon.

Abstract: Extra heavy lube base stocks are separated from heavy lube oils with a polar solvent in an amount sufficient to form a first light phase and a second heavy phase. The phases are then separated and the solvent is removed from the second heavy phase to yield an extra heavy lube.

Abstract: An automatic titration apparatus for optically determining incompatibility of petroleum oils. The apparatus includes reservoirs for oil and solvent, a sealed temperature-controlled mixing vessel, including a liquid mixer, pumps and transfer lines for dispensing oil and solvent from said reservoirs to said mixing vessel wherein oil and solvent are mixed to form a mixture, an aggregate detector, transfer lines for transferring said mixture to the aggregate detector, and a computer programmed to operate and monitor all elements of said apparatus.